Skip to main content

Advertisement

SpringerLink
Log in

First-Line Therapy for Nodal T-cell Non-Hodgkin Lymphomas: an Unmet Need in Hematology

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purposeof Review

The main aim of this review is to summarize first-line therapy of nodal T-cell non-Hodgkin lymphoma.

Recent Findings

Current treatment with CHOP chemotherapy results in poor outcomes in the majority of patients. However, there are advances within the field. First breakthrough is the ECHELON-2 trial which showed that the addition of brentuximab vedotin improves outcomes in anaplastic large cell lymphoma. However, other types of peripheral T-cell non-Hodgkin lymphoma were underrepresented with optimal treatment not known. Second breakthrough is an increase of autologous stem cell transplantation usage in the first complete metabolic remission, except in ALK + anaplastic large cell lymphoma, offering better disease control.

Summary

Despite advances in the field, CHOP remains the standard treatment for the majority of these lymphomas, but multiple trials are underway with the aim to improve this unmet need in hematology and, hopefully, leading us to a new era in the treatment of peripheral T-cell lymphomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90. https://doi.org/10.1182/blood-2016-01-643569.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti et al. (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 36:1720–1748. https://doi.org/10.1038/s41375-022-01620-2

  3. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229–53. https://doi.org/10.1182/blood.2022015851.

    Article  CAS  PubMed  Google Scholar 

  4. Vega F, Amador C, Chadburn A, Hsi ED, Slack G, Medeiros LJ, et al. Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. Mod Pathol. 2022;35:306–18. https://doi.org/10.1038/s41379-021-00937-0.

    Article  CAS  PubMed  Google Scholar 

  5. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92:1240–51. https://doi.org/10.1093/jnci/92.15.1240.

    Article  CAS  PubMed  Google Scholar 

  6. Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30. https://doi.org/10.1200/JCO.2008.16.4558.

    Article  PubMed  Google Scholar 

  7. Jaffe ES, Harris NL, Stein H, et al editors. World Health Organization Classification of Tumors: pathology and genetics of tumors of hematopoietic and lymphoid tissues. Lyon: France, IARC Press; 2001.

    Google Scholar 

  8. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–6. https://doi.org/10.1056/NEJM199304083281404.

    Article  CAS  PubMed  Google Scholar 

  9. Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124:1570–7. https://doi.org/10.1182/blood-2014-04-573089.

    Article  CAS  PubMed  Google Scholar 

  10. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496–504. https://doi.org/10.1182/blood-20pi8-01-134270.

    Article  CAS  PubMed  Google Scholar 

  11. Shustov A, Cabrera ME, Civallero M, Bellei M, Ko YH, Manni M, et al. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. Blood Adv. 2021;5:640–8. https://doi.org/10.1182/bloodadvances.2020001581.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94. https://doi.org/10.1056/NEJM199309303291402.

    Article  Google Scholar 

  13. Abouyabis AN, Shenoy PJ, Sinha RA, Flowers CR, Lechowicz MJ. Systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011;2011:623924. https://doi.org/10.5402/2011/623924.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. •• Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, et al. T-Cell Lymphomas, Version 2.2022, NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:285–308. https://doi.org/10.6004/jnccn.2022.0015Usually precise, these guidelines are vague in terms of treatment of T-cell lymphoma.

    Article  CAS  PubMed  Google Scholar 

  15. Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116:3418–25. https://doi.org/10.1182/blood-2010-02-270785.

    Article  CAS  PubMed  Google Scholar 

  16. Dunleavy K, Pittaluga S, Shovlin M, Roschewski M, Lai C, Steinberg SM, et al. Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. Haematologica. 2016;101:27–9. https://doi.org/10.3324/haematol.2015.131151.

    Article  CAS  Google Scholar 

  17. Maeda Y, Nishimori H, Yoshida I, Hiramatsu Y, Uno M, Masaki Y, et al. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica. 2017;102:2097–103. https://doi.org/10.3324/haematol.2017.167742.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hapgood G, Stone JM, Zannino D, George A, Marlton P, Prince HM, et al. A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2019;60:904–11. https://doi.org/10.1080/10428194.2018.1516873.

    Article  CAS  PubMed  Google Scholar 

  19. Escalón MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D Anderson Cancer Center experience Cancer. 2005;103:2091–8. https://doi.org/10.1002/cncr.20999.

    Article  Google Scholar 

  20. Sung HJ, Kim SJ, Seo HY, et al. Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study. Br J Haematol. 2006;134:45–53. https://doi.org/10.1111/j.1365-2141.2006.06124.x.

    Article  PubMed  Google Scholar 

  21. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J. Lymphoma classification–from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol. 2000;11:3–10.

    Article  PubMed  Google Scholar 

  22. d’Amore F, Relander T, Lauritzsen GF, Antunen E, Hagberg H, Anderson H, et al. (2012) Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9. https://doi.org/10.1200/JCO.2011.40.2719.

    Article  CAS  PubMed  Google Scholar 

  23. Cheson BD, Horning SJ, Coiffier B, Hipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored Int Working Group J Clin Oncol. 1999;17:1244. https://doi.org/10.1200/JCO.1999.17.4.12444.

    Article  CAS  Google Scholar 

  24. d’Amore F, Relander T, Lauritzsen GF, Jatunsen E, Hagberg H, Anderson H, et al. Ten years median follow-up of the nordic nlg-t-01 trial on CHOEP and upfront autologous transplantation in peripheral T-cell lymphomas in Hematologic Oncology 2015. https://onlinelibrary.wiley.com/doi/10.1002/hon.2227. Accessed 19 Sept 2022

  25. Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29:715–23. https://doi.org/10.1093/annonc/mdx787.

  26. Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019;125:1507–1517. https://doi.org/10.1002/cncr.31861

  27. El-Asmar J, Reljic T, Ayala E, Hamadani M, Nishihori T, Kumar A, et al. Efficacy of high-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphomas as front-line consolidation or in the relapsed/refractory setting: a systematic review/meta-analysis. Biol Blood Marrow Transplant. 2016;22:802–14. https://doi.org/10.1016/j.bbmt.2015.12.004.

    Article  PubMed  Google Scholar 

  28. •• Fox CP, Ahearne MJ, Pettengell R, Dearden C, El-Sharkawi D, Kassam S, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Br J Haematol. 2022;196:507–22. https://doi.org/10.1111/bjh.17951. The precise guidelines using the GRADE system as the most thorough guidelines in T-cell lymphoma.

    Article  PubMed  Google Scholar 

  29. El-Asmar J, Reljic T, Ayala E, Hamadani M, Nishihori T, Kumar A, et al. Efficacy of high-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphomas as front-line consolidation or in the relapsed/refractory setting: a systematic review/meta-analysis. Biol Blood Marrow Transplant. 2016;22:802–14.

  30. • Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. 2021;137:2646–56. Proof-of-concept study on the role of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphoma.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Gribben JG, Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol. 2009;144:818–31. https://doi.org/10.1111/j.1365-2141.2008.07557.x.

    Article  CAS  PubMed  Google Scholar 

  32. • Wulf GG, Altmann B, Ziepert M, D’Amore F, Held G, Greil R, et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. Leukemia. 2021;35:143–55. https://doi.org/10.1038/s41375-020-0838-5. Example how addition of drug X to CHOP backbone is in majority of trials futile in this area.

  33. d’Amore F, Leppa S, Gomes de Silva M, Relander T, Lauritzsen GF, De Nully Brown P et al. Final analysis of the front-line Phase III randomized ACT-1 Trial in younger patients with systemic peripheral T-cell lymphoma treated with CHOP chemotherapy with or without alemtuzumab and consolidated by autologous hematopoietic stem cell transplant. In: 60th American Society of Hematology Annual Meeting and Exposition.  Blood 2018.  https://ashpublications.org/blood/article/132/Supplement%201/998/265989/Final-Analysis-of-the-Front-Line-Phase-III. Accessed 20 Sept 2022. https://doi.org/10.1182/blood-2018-99-112076

  34. Altmann B, Wulf G, Truemper L, d’Amore F, Relander T, Toldbod H et al. Alemtuzumab added to CHOP for treatment of peripheral T-Cell lymphoma (PTCL) in previously untreated young and elderly patients: pooled analysis of the international ACT-1/2 Phase III Trials. In: 60th American Society of Hematology Annual Meeting and Exposition. Blood 2018. https://ashpublications.org/blood/article/132/Supplement%201/1622/273276/Alemtuzumab-Added-to-CHOP-for-Treatment-of. Accessed 20 Sept 2022. https://doi.org/10.1182/blood-2018-99-112076ht112076

  35. Chu Y, Zhou X, Wang X. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress. J Hematol Oncol. 2021;5(14):88. https://doi.org/10.1186/s13045-021-01097-z.

    Article  CAS  Google Scholar 

  36. •• Horwitz S, O’Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229–40. https://doi.org/10.1016/S0140-6736(18)32984-2. A breakthrough trial in ALCLs showing that addition of brentuximab vedotin to CHP backbone improves the outcomes; however, other histologies are underrepresented leaving the optimal therapy unknown.

    Article  CAS  PubMed  Google Scholar 

  37. Savage KJ, Horwitz SM, Advani RA, Christensen JH, Domingo-Domenech E, Rossi G,  et al. An exploratory analysis of brentuximab vedotin plus CHP (A+CHP) in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas (ECHELON-2): impact of consolidative stem cell transplant. In: 61st ASH Annual Meeting and Exposition. Blood 2019. https://ashpublications.org/blood/article/134/Supplement_1/464/426343/An-Exploratory-Analysis-of-Brentuximab-Vedotin. Accessed 25 Sept 2022. https://doi.org/10.1182/blood-2019-122781

  38. Horwitz S, O’Connor OA, Pro B, Trümper L, Iyer S, Advani R, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33:288–98.

    Article  CAS  PubMed  Google Scholar 

  39. European Medicine Agency. Adcetris. In European Medicine Agency, 2022. https://www.ema.europa.eu/en/medicines?search_api_views_fulltext=brentu. Accessed 1 Dec 2022.

  40. Wang ES, O’Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma. 2003;44:1027–35. https://doi.org/10.1080/1042819031000077124.

    Article  CAS  PubMed  Google Scholar 

  41. Advani RH, Ansell SM, Lehowicz MJ, et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Br J Haematol. 2016;172:535–44. https://doi.org/10.1111/bjh.13855.

    Article  CAS  PubMed  Google Scholar 

  42. Shustov A, Johnston BJ, Klaus Barta S, Bhat G, Reddy G, Oki Y. Pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in previously untreated patients with peripheral T-cell lymphoma (PTCL): a Phase 1 Dose-Escalation Study. In: 59th ASH Meeting and Exposition. Blood 2017. https://ashpublications.org/blood/article/130/Supplement%201/818/83528/Pralatrexate-in-Combination-with-Cyclophosphamide Accesed 1 Dec 2022.

  43. ClinicalTrials.gov. National Library of Medicine (U.S.). (August 22, 2011- November 19, 2021) Study of pralatrexate versus observation following CHOP-based chemotherapy in previously undiagnosed peripheral T-cell lymphoma patients. Identifier NCT01420679. Retrieved December 1 from https://www.clinicaltrials.gov/ct2/show/NCT01420679

  44. Martinez-Høyer S, Karsan A. Mechanisms of lenalidomide sensitivity and resistance. Exp Hematol. 2020;91:22–31.

    Article  PubMed  Google Scholar 

  45. Lemonnier F, Safar V, Beldi-Ferchiou A, et al. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. Blood Adv. 2021;5:539–48. https://doi.org/10.1182/bloodadvances.2020003081.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68. https://doi.org/10.1200/JCO.2013.54.8800.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Moskowitz AJ, Horwitz SM. Targeting histone deacetylases in T-cell lymphoma. Leuk Lymphoma. 2017;58:1306–19. https://doi.org/10.1080/10428194.2016.1247956.

    Article  CAS  PubMed  Google Scholar 

  48. Zhang Q, Wang S, Chen J, Yu Z. Histone Deacetylases (HDACs) Guided novel therapies for T-cell lymphomas. Int J Med Sci. 2019;16:424–42. https://doi.org/10.7150/ijms.30154.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. •• Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas RO, Ysebaert L, et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-Cell lymphoma: results of the Ro-CHOP Phase III Study (Conducted by LYSA). J Clin Oncol. 2022;40:242–51. https://doi.org/10.1200/JCO.21.01815. Despite being negative, this trial established CHOP as the current standard of care in majority of peripheral T-cell NHL.

    Article  CAS  PubMed  Google Scholar 

  50. Xie Y, Jaffe ES. How I Diagnose angioimmunoblastic T-cell lymphoma. Am J Clin Pathol. 2021;156:1–14. https://doi.org/10.1093/ajcp/aqab090.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Kim SJ, Shin DY, Kim JS, Yoon DH, Lee WS, Lee H, et al. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. Ann Oncol. 2016;27:712–8. https://doi.org/10.1093/annonc/mdv624.

    Article  CAS  PubMed  Google Scholar 

  52. Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer. 2012;48:3223–31. https://doi.org/10.1016/j.ejca.2012.06.003.

    Article  CAS  PubMed  Google Scholar 

  53. Ganjoo K, Hong F, Horning SJ, Gascoyne RD, Natkunam Y, Swinnen LJ, et al. N Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma. 2014;55:768–72. https://doi.org/10.3109/10428194.2013.816700.

    Article  CAS  PubMed  Google Scholar 

  54. Wang J, Su N, Fang Y, Ma S, Zhang Y, Cai J, et al. Comparison of chemotherapy combined with chidamide versus chemotherapy in the frontline treatment for peripheral T-cell lymphoma. Front Immunol. 2022;13:835103. https://doi.org/10.3389/fimmu.2022.835103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Chen Z, Huang H, Li X, Fang X, Wang Z, Hong H, et al. Chemotherapy plus radiotherapy versus chemotherapy alone for patients with peripheral T-cell lymphoma, not otherwise specified. Front Oncol. 2021;11:607145. https://doi.org/10.3389/fonc.2021.607145.

    Article  PubMed  PubMed Central  Google Scholar 

  56. •• Angelos MG, Ballard HJ, Barta SK. Advances and personalized approaches in the frontline treatment of T-cell lymphomas. J Pers Med. 2022;12:267. https://doi.org/10.3390/jpm12020267. An overview of potential novel treatment paradigm in peripheral T-NHL.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge Aron Belso for creating Figure 1.

Author information

Authors and Affiliations

  1. Division of Hematology, Clinical Hospital Merkur, Zajčeva 19, 10000, Zagreb, Croatia

    Vibor Milunović, Inga Mandac Smoljanović, Martina Bogeljić Patekar, Viktor Zatezalo, Marin Kursar, Delfa Radić-Krišto & Slobodanka Ostojić Kolonić

  2. School of Medicine, University of Zagreb, Zagreb, Croatia

    Inga Mandac Smoljanović, Delfa Radić-Krišto, Slobodanka Ostojić Kolonić & Slavko Gašparov

  3. Clinical Department of Pathology and Cytology, Clinical Hospital Merkur, Zagreb, Croatia

    Slavko Gašparov

Authors
  1. Vibor Milunović
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Inga Mandac Smoljanović
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martina Bogeljić Patekar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Viktor Zatezalo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marin Kursar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Delfa Radić-Krišto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Slobodanka Ostojić Kolonić
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Slavko Gašparov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vibor Milunović.

Ethics declarations

Conflict of Interest

Author Vibor Milunović has received a research grant, personal consulting fees, speaking honoraria, and travel grants from Takeda. Author Inga Mandac Smoljanović has received research grant and speaking honoraria from Takeda. Author Martina Bogeljić Patekar does not have any competing interests to declare that are relevant to the content of this article. Author Viktor Zatezalo does not have any competing interests to declare that are relevant to the content of this article Marin. Author Marin Kusar Marin received speaking honoraria from Takeda. Author Delfa Radić Krišto has received honoraria for speaking and for personal consulting fees for participating on the Takeda advisory board. Author Slobodanka Ostojić Kolonić has received a research grant and speaking honoraria from Takeda. Author Slavko Gašparov does not have any competing interests to declare that are relevant to the content of this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Milunović, V., Smoljanović, I.M., Patekar, M.B. et al. First-Line Therapy for Nodal T-cell Non-Hodgkin Lymphomas: an Unmet Need in Hematology. Curr Oncol Rep 25, 813–824 (2023). https://doi.org/10.1007/s11912-023-01400-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-023-01400-w

Keywords

Search

Navigation